

Testing of the Guidance on Risk Assessment of Living Modified Organisms

#20



COMPLETE

Collector: BCH website (Website Survey)

Started: Wednesday, February 19, 2014 8:34:57 AM

Last Modified: Wednesday, February 19, 2014 8:40:28 AM

Time Spent: 00:05:31

PAGE 1

Q1: Type of submission:

Party

PAGE 2

Q2: Name of the Party:

Egypt

Q3: Person submitting this questionnaire:

Full Name:

Ossama El-Tayeb

Email Address:

omtayeb@link.net

Q4: Institution(s) or organization(s) that participated in the testing:

Government authority(ies), Academic institution(s)

Q5: Context in which the testing was conducted

Individual exercise(s)

Q6: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Risk Assessment 1:

<http://bch.cbd.int/database/record.shtml?documentid=48362>

Q7: In what language was the Guidance tested?

English

PAGE 3

Q8: Name of the other Government:

Respondent skipped this question

Q9: Person submitting this questionnaire:

Respondent skipped this question

Q10: Institution(s) or organization(s) that participated in the testing:

Respondent skipped this question

Q11: Context in which the testing was conducted

Respondent skipped this question

Q12: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Respondent skipped this question

Q13: In what language was the Guidance tested?

Respondent skipped this question

PAGE 4

| | |
|--|---|
| Q14: Name of the organization: | <i>Respondent skipped this question</i> |
| Q15: Person submitting this questionnaire: | <i>Respondent skipped this question</i> |
| Q16: Institution(s) or organization(s) that participated in the testing: | <i>Respondent skipped this question</i> |
| Q17: Context in which the testing was conducted | <i>Respondent skipped this question</i> |
| Q18: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml?documentid=104904 and http://bch.cbd.int/database/record.shtml?documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing. | <i>Respondent skipped this question</i> |
| Q19: In what language was the Guidance tested? | <i>Respondent skipped this question</i> |

PAGE 5

| | |
|--|-----|
| Q20: Would you like to submit an evaluation of the following section of the Guidance: Part I: The Roadmap for Risk Assessment | Yes |
|--|-----|

PAGE 6

| | |
|--|---|
| Q21: This section of the Guidance is practical.1 (no label) | Strongly Agree |
| Q22: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: | <i>Respondent skipped this question</i> |
| Q23: This section of the Guidance is useful or has utility.2 (no label) | Strongly Agree |
| Q24: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: <ul style="list-style-type: none"> - Issues of human health in the context of risk assessment of LMOs are still not well reflected in the roadmap. - There is need for more direct reference to socio-economic considerations which could be geographically and popularly relevant in decision making for specific LMOs.. - The preparation of concrete examples, including LMOs case studies, to be used in conjunction with the roadmap to assist in training and capacity building activities in developing countries would add to the usefulness of the guidance materials prepared. | |
| Q25: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 (no label) | Strongly Agree |

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q26: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q27: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Agree

Q28: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q29: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

The roadmap shows how conducting risk assessment relates to other stages in the overall appraisal process leading to decision making. It clearly emphasizes the importance of the pre-risk assessment scoping process and the post-risk assessment evaluation of its outcomes.

The roadmap encourages serious brainstorming of those involved in risk assessment-decision making as to what information they may legitimately ask for and how to evaluate such information and integrate it into a package would help decision making.

PAGE 7

Q30: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LMOs with stacked genes or traits

Yes

PAGE 8

Q31: This section of the Guidance is practical.1

(no label)

Agree

Q32: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q33: This section of the Guidance is useful or has utility.2

(no label)

Agree

Q34: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q35: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Agree

Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q37: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Agree

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q38: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q39: Here you may provide further details to explain your answers in evaluating this section of the Guidance: *Respondent skipped this question*

PAGE 9

Q40: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM crops with tolerance to abiotic stress Yes

PAGE 10

Q41: This section of the Guidance is practical.1
(no label) Agree

Q42: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q43: This section of the Guidance is useful or has utility.2
(no label) Strongly Agree

Q44: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q45: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3
(no label) Strongly Agree

Q46: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q47: This section of the Guidance takes into account past and present experiences with LMOs.4
(no label) Agree

Q48: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q49: Here you may provide further details to explain your answers in evaluating this section of the Guidance: *Respondent skipped this question*

PAGE 11

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q50: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM mosquitoes

Yes

PAGE 12

Q51: This section of the Guidance is practical.1

(no label)

Neutral

Q52: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q53: This section of the Guidance is useful or has utility.2

(no label)

Neutral

Q54: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q55: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Agree

Q56: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q57: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Neutral

Q58: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q59: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 13

Q60: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM trees

Yes

PAGE 14

Q61: This section of the Guidance is practical.1

(no label)

Agree

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q62: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q63: This section of the Guidance is useful or has utility.2

(no label)

Agree

Q64: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q65: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Agree

Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q67: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Agree

Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q69: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 15

Q70: Would you like to submit an evaluation of the following section of the Guidance: Part III: Monitoring of LMOs Released into the Environment

Yes

PAGE 16

Q71: This section of the Guidance is practical.1

(no label)

Strongly Agree

Q72: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q73: This section of the Guidance is useful or has utility.2

(no label)

Strongly Agree

Q74: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q75: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.³

(no label)

Strongly Agree

Q76: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q77: This section of the Guidance takes into account past and present experiences with LMOs.⁴

(no label)

Neutral

Q78: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

The section on monitoring of the guidance provides a useful approach to develop a monitoring plan focusing on “what, how long, how and where to monitor” and how to communicate the results of both general and case specific monitoring. It could however benefit from further focusing and articulation.

Q79: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 17

Q80: Would you like to submit an evaluation of the following section of the Guidance: Background Documents

Yes

PAGE 18

Q81: This section of the Guidance is practical.¹

(no label)

Strongly Agree

Q82: This section of the Guidance is useful or has utility.²

(no label)

Strongly Agree

Q83: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.³

(no label)

Strongly Agree

Q84: This section of the Guidance takes into account past and present experiences with LMOs.⁴

(no label)

Strongly Agree

PAGE 19

Q85: Please use the space below if you wish to provide additional feedback regarding the testing of the Guidance on Risk Assessment of Living Modified Organisms:

Respondent skipped this question